{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T02:57:22Z","timestamp":1777345042655,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T00:00:00Z","timestamp":1449878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Spanish Ministry of Health and Social Politics","award":["Grant number TRA-112"],"award-info":[{"award-number":["Grant number TRA-112"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s12026-015-8747-9","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T06:14:28Z","timestamp":1449900868000},"page":"548-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity"],"prefix":"10.1007","volume":"64","author":[{"given":"Ricardo","family":"Garc\u00eda-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ascensi\u00f3n","family":"L\u00f3pez-D\u00edaz-de-Cerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Panizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Rodr\u00edguez-Calvillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Pena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayte","family":"Olave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Panizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Inog\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,12]]},"reference":[{"key":"8747_CR1","first-page":"925","volume-title":"Clinical immunology. Principles and practice","author":"TL Whiteside","year":"2013","unstructured":"Whiteside TL, Robinson B, June CH, Lotze M. Principles of tumor immunology. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew A, Weyand CM, editors. Clinical immunology. Principles and practice. 4th ed. St. Louis: Elsevier; 2013. p. 925\u201334.","edition":"4"},{"key":"8747_CR2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1201\/b13424-99","volume-title":"The lymphoid neoplams","author":"B Herreros","year":"2010","unstructured":"Herreros B, Sanchez-Agulere A, Piris MA. Lymphoma microenvironment. In: Magrath IT, Bathia K, Boffetta P, Dearden C, Diehl V, Gascoyne RD, Muller-Hermelink HK, Potter M, Rohatiner A, editors. The lymphoid neoplams. 3rd ed. London: Oxford University Press; 2010. p. 1552.","edition":"3"},{"key":"8747_CR3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1201\/b13424-37","volume-title":"The lymphoid neoplams","author":"RD Gascoyne","year":"2010","unstructured":"Gascoyne RD. Follicular lymphoma. In: Magrath IT, Bathia K, Boffetta P, Dearden C, Diehl V, Gascoyne RD, Muller-Hermelink HK, Potter M, Rohatiner A, editors. The lymphoid neoplams. 3rd edn. London: Oxford University Press; 2010. p. 513.","edition":"3"},{"key":"8747_CR4","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1084\/jem.20082271","volume":"205","author":"JH Wang","year":"2008","unstructured":"Wang JH, Alt FW, Gostissa M, Murphy M, Alimzhanov MB, Coakley KM, et al. Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J Exp Med. 2008;205:3079\u201390.","journal-title":"J Exp Med"},{"key":"8747_CR5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/rheumatology\/ken178","volume":"47","author":"R Garc\u00eda-Mu\u00f1oz","year":"2008","unstructured":"Garc\u00eda-Mu\u00f1oz R, Panizo E, Rodriguez-Otero P, Mugueta-Uriaque MC, Rifon J, Llorente L, et al. Systemic lupus erythematosus and Franklin\u2019s disease: when the somatic mutation mechanism makes a mistake. Rheumatol Oxf. 2008;47:1105\u20136.","journal-title":"Rheumatol Oxf"},{"key":"8747_CR6","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1172\/JCI63186","volume":"122","author":"R Kridel","year":"2012","unstructured":"Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122:3424\u201331.","journal-title":"J Clin Invest"},{"key":"8747_CR7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00277-012-1460-z","volume":"91","author":"R Garc\u00eda-Mu\u00f1oz","year":"2012","unstructured":"Garc\u00eda-Mu\u00f1oz R, Galiacho VR, Lorente L. Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol. 2012;91:981\u201396.","journal-title":"Ann Hematol"},{"key":"8747_CR8","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2012-08-446732","volume":"121","author":"VK Nganga","year":"2013","unstructured":"Nganga VK, Palmer VL, Naushad H, Kassmeier MD, Anderson DK, Perry GA, et al. Accelerated progression of chronic lymphocytic leukemia in E\u03bc-TCL1 mice expressing catalytically inactive RAG1. Blood. 2013;121:3855\u201366.","journal-title":"Blood"},{"key":"8747_CR9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/imm.12285","volume":"142","author":"R Garc\u00eda-Mu\u00f1oz","year":"2014","unstructured":"Garc\u00eda-Mu\u00f1oz R, Lorente L. Chronic lymphocytic leukemia: Could immunological tolerance mechanisms be the origin of lymphoid neoplasms? Immunology. 2014;142:536\u201350.","journal-title":"Immunology"},{"key":"8747_CR10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.leukres.2009.05.008","volume":"33","author":"R Garc\u00eda-Mu\u00f1oz","year":"2009","unstructured":"Garc\u00eda-Mu\u00f1oz R, Panizo C, Bendandi M, Llorente L. Autoimmunity and lymphoma: Is mantle cell lymphoma a mistake of the receptor editing mechanism? Leuk Res. 2009;33:1437\u20139.","journal-title":"Leuk Res"},{"key":"8747_CR11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaut.2014.10.005","volume":"56","author":"R Garc\u00eda-Mu\u00f1oz","year":"2015","unstructured":"Garc\u00eda-Mu\u00f1oz R, Feliu J, Llorente L. The top ten clues to understand the origin of chronic lymphocytic leukemia (CLL). J Autoimmun. 2015;56:81\u20136.","journal-title":"J Autoimmun"},{"issue":"1 Suppl","key":"8747_CR12","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bbmt.2011.10.033","volume":"18","author":"WJ Murphy","year":"2012","unstructured":"Murphy WJ, Parham P, Miller JS. NK cells\u2014from bench to clinic. Biol Blood Marrow Transplant. 2012;18(1 Suppl):S2\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"8747_CR13","first-page":"395","volume-title":"Fundamental Immunology","author":"WM Yokoyama","year":"2013","unstructured":"Yokoyama WM. Natural killer cells. In: Paul WE, editor. Fundamental Immunology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 395\u2013431.","edition":"7"},{"key":"8747_CR14","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P","volume":"79","author":"S Coca","year":"1997","unstructured":"Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79:2320\u20138.","journal-title":"Cancer"},{"key":"8747_CR15","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B cell cytotoxicity. Blood. 2010;115:4393\u2013402.","journal-title":"Blood"},{"key":"8747_CR16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","volume":"12","author":"S Herter","year":"2014","unstructured":"Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the type II CD20 antibody GA101(Obinutuzumab) compared with Rituximab and Ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2014;12:2031\u201342.","journal-title":"Mol Cancer Ther"},{"key":"8747_CR17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.leukres.2012.11.015","volume":"37","author":"E Leprevotte","year":"2013","unstructured":"Leprevotte E, Ysebaert L, Klein C, Valleron W, Blanc A, Groos E, et al. Endogenous IL-8 acts as a CD16 co-activator for natural killer mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. Leuk Res. 2013;37:440\u20136.","journal-title":"Leuk Res"},{"key":"8747_CR18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.beha.2011.02.007","volume":"24","author":"D Jong de","year":"2011","unstructured":"de Jong D, Fest T. The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol. 2011;24:135\u201346.","journal-title":"Best Pract Res Clin Haematol"},{"key":"8747_CR19","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. New Engl J Med. 2004;351:2159\u201369.","journal-title":"New Engl J Med"},{"key":"8747_CR20","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","volume":"93","author":"R Garc\u00eda-Mu\u00f1oz","year":"2014","unstructured":"Garc\u00eda-Mu\u00f1oz R, Izquierdo-Gil A, Mu\u00f1oz A, Roldan-Galiacho V, Rabasa P, Panizo C. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol. 2014;93:1879\u201387.","journal-title":"Ann Hematol"},{"key":"8747_CR21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/onc.2009.416","volume":"29","author":"F Pag\u00e9s","year":"2010","unstructured":"Pag\u00e9s F, Galon J, Dieu-Nosjean MC, Tartour E, Saut\u00e9s-Fridman C, Fridman WH. Immune filtration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093\u2013102.","journal-title":"Oncogene"},{"key":"8747_CR22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1365-2141.2006.06232.x","volume":"134","author":"M Siddiqui","year":"2006","unstructured":"Siddiqui M, Ristow K, Markovic SN, Witzing TE, Haberman TM, Colgan JP, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006;134:596\u2013601.","journal-title":"Br J Haematol"},{"key":"8747_CR23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.bbmt.2008.04.013","volume":"14","author":"LF Porrata","year":"2008","unstructured":"Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008;14:807\u201316.","journal-title":"Biol Blood Marrow Transplant"},{"key":"8747_CR24","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMoa051424","volume":"353","author":"F Pag\u00e9s","year":"2005","unstructured":"Pag\u00e9s F, Berger A, Camus M, Sanchez Cabo F, Costes A, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654\u201366.","journal-title":"N Engl J Med"},{"key":"8747_CR25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1201\/b13424-37","volume-title":"The lymphoid neoplasms","author":"RD Gascoyne","year":"2010","unstructured":"Gascoyne RD. Follicular lymphoma. In: Magrath IT, Bhatia K, Boffetta P, Dearden C, Diehl V, Gascoyne RD, M\u00fcller-Hermelink HK, et al., editors. The lymphoid neoplasms. 3rd ed. London: Hodder\/Arnold; 2010. p. 513\u201338.","edition":"3"},{"key":"8747_CR26","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.4049\/jimmunol.1201363","volume":"190","author":"S Rawal","year":"2013","unstructured":"Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol. 2013;190:6681\u201393.","journal-title":"J Immunol"},{"key":"8747_CR27","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1078-0432.CCR-1087-3","volume":"10","author":"WL Gluck","year":"2004","unstructured":"Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, et al. Phase I studies of interleukin (IL)-2 and rituximab in B cell non-Hodgkin\u2019s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10:2253\u201364.","journal-title":"Clin Cancer Res"},{"key":"8747_CR28","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1182\/blood-2013-02-482570","volume":"121","author":"D Rudnicka","year":"2013","unstructured":"Rudnicka D, Oszmiana A, Flinch DK, Strickland I, Schofield DJ, Lowe DC, et al. Rituximab causes polarization of B cells that augments its therapeutic function in NK-cell mediated antibody-dependent cellular cytotoxicity. Blood. 2013;121:4694\u2013702.","journal-title":"Blood"},{"key":"8747_CR29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/2326-6066.CIR-13-0158","volume":"2","author":"J Du","year":"2014","unstructured":"Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, et al. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res. 2014;2:878\u201389.","journal-title":"Cancer Immunol Res"},{"key":"8747_CR30","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.leukres.2013.07.038","volume":"37","author":"D Shafer","year":"2013","unstructured":"Shafer D, Smith MR, Borghaei H, Millenson MM, Li T, Litwin S, et al. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk Res. 2013;37:1213\u20135.","journal-title":"Leuk Res"},{"key":"8747_CR31","doi-asserted-by":"crossref","unstructured":"Rossi G, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, et al. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatment after relapse in follicular lymphoma. The Reffoll study by the Fondazione Italiana Linfomi. Am J Hematol. doi: 10.1002\/ajh.23872 .","DOI":"10.1002\/ajh.23872"},{"key":"8747_CR32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3 randomized controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"key":"8747_CR33","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","volume":"31","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F, Radford J, Van Hoff A, Botto B, Rohatiner AZ, Salles G, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advances state follicular non-Hodgkin lymphoma: updated results after a median follow-up 7.3\u00a0years from the international randomized, phase III first\u2014lineindolent trial. J Clin Oncol. 2013;31:1977\u201383.","journal-title":"J Clin Oncol"},{"key":"8747_CR34","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K Besien van","year":"2003","unstructured":"van Besien K, Loberiza RJ, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521\u20139.","journal-title":"Blood"},{"key":"8747_CR35","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/djj358","volume":"98","author":"S Inog\u00e9s","year":"2006","unstructured":"Inog\u00e9s S, Rodriguez-Calvillo M, Zavalegui N, L\u00f3pez-D\u00edaz de Cerio A, Villanueva H, Soria E, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98:1292\u2013301.","journal-title":"J Natl Cancer Inst"},{"key":"8747_CR36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1200\/JCO.1992.10.1.33","volume":"10","author":"JS Weber","year":"1992","unstructured":"Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1992;10:33\u201340.","journal-title":"J Clin Oncol"},{"key":"8747_CR37","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/bcj.2013.32","volume":"3","author":"E Decaup","year":"2013","unstructured":"Decaup E, Jean C, Laurent C, Gravelle P, Fruchon S, Capilla F, et al. Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model. Blood Cancer J. 2013;3:e131.","journal-title":"Blood Cancer J"},{"key":"8747_CR38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","volume":"10","author":"S Dalle","year":"2011","unstructured":"Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, et al. Preclinical studies on the mechanisms of action and the anti-lymphoma activity of the novel anti-cd20 antibody GA101. Mol Cancer Ther. 2011;10:178\u201385.","journal-title":"Mol Cancer Ther"},{"key":"8747_CR39","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","volume":"122","author":"J Radford","year":"2013","unstructured":"Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122:1137\u201343.","journal-title":"Blood"},{"key":"8747_CR40","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","volume":"31","author":"GA Salles","year":"2013","unstructured":"Salles GA, Morschhauserf F, Solal-C\u00e9ligny P, Thieblemont C, Lamy T, Tilly H, et al. Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non Hodgkin Lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2920\u20136.","journal-title":"J Clin Oncol"},{"key":"8747_CR41","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.4049\/jimmunol.181.4.2916","volume":"181","author":"PV Beum","year":"2008","unstructured":"Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody dependent cellular cytotoxicity of Rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol. 2008;181:2916\u201324.","journal-title":"J Immunol"},{"key":"8747_CR42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0609.1981.tb00470.x","volume":"27","author":"M Jakobisiak","year":"1981","unstructured":"Jakobisiak M, Janowska-Wieczorek A, Dobaczewska H, Kantoch M, Marczak M, Oblakowski P, et al. Decreased antibody-dependent cellular cytotoxicity in various types of leukaemia in man. Scan J Haematol. 1981;27:181\u20135.","journal-title":"Scan J Haematol"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-015-8747-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12026-015-8747-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-015-8747-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T11:25:18Z","timestamp":1567423518000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12026-015-8747-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,12]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["8747"],"URL":"https:\/\/doi.org\/10.1007\/s12026-015-8747-9","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,12]]}}}